TrialThe Lancet. Oncology2018
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Marina Chiara Garassino et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
364 papers cite itlatest 60 shown
this paperpooled ittrialcites it